ArticleFrontiers in medicine2025
The regulatory and scientific context in the study of the medicinal use of cannabis in Peru.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cannabis has been historically utilized for medicinal purposes worldwide. However, it was classified as a controlled substance under the United Nations' 1961 Single Convention on Narcotic Drugs, alongside coca and opium. This classification influenced many countries, including Peru, to adopt prohibitionist policies, even though the convention allowed medicinal use, scientific research, and even horticulture. Recent decades have witnessed a renewed interest in the therapeutic potential of cannabis, leading countries like Canada to establish medicinal frameworks. In 2017, Peru passed Law 30681, legalizing cannabis for medicinal use, scientific research, and pharmaceutical production through the obtention of licenses, and in 2021, Law 31312 allowed patient associations to grow and produce cannabis. Nevertheless, these regulations have proven insufficient, as no domestic production has taken place due to complex licensing requirements for both pharmaceutical companies and patient associations; the same scenario applies for scientific purposes. This article examines the regulatory challenges surrounding cannabis in Peru, focusing on scientific research. While the 2019 regulatory framework aimed to support medicinal access, it has fallen short in practice. Hard licensing process and stringent requirements have restricted scientific investigation, limiting it to observational studies and analysis of cannabis products available on the informal market. A recent study conducted between 2019 and 2023 analyzed native cannabis strains in four regions of Peru, highlighting the therapeutic potential of local cultivars. However, regulatory hurdles, such as sample obtention, transportation, and analysis, pose significant risks to researchers. The study suggests that Peru's cannabis regulation requires urgent reforms, including simplifying licensing for scientific research, facilitating access for patients, and distinguishing personal cultivation from illicit drug trafficking. These changes are necessary to harness the medicinal potential of cannabis and support the development of local research and the possibility of local production.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.